Abbott Laboratories (SWX:ABT)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
93.50
0.00 (0.00%)
Sep 30, 2024, 9:05 AM CET
2.75%
Market Cap 191.10B
Revenue (ttm) 37.43B
Net Income (ttm) 11.89B
Shares Out n/a
EPS (ttm) 6.81
PE Ratio 16.07
Forward PE 25.21
Dividend 1.99 (2.13%)
Ex-Dividend Date Apr 15, 2025
Volume 20
Average Volume n/a
Open 92.00
Previous Close 93.50
Day's Range 92.00 - 93.50
52-Week Range 89.00 - 96.00
Beta 0.68
RSI 31.18
Earnings Date Jul 16, 2025

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1888
Employees 114,000
Stock Exchange SIX Swiss Exchange
Ticker Symbol ABT
Full Company Profile

Financial Performance

In 2024, Abbott Laboratories's revenue was $41.95 billion, an increase of 4.59% compared to the previous year's $40.11 billion. Earnings were $13.35 billion, an increase of 134.19%.

Financial numbers in USD Financial Statements

News

Faulty prostate cancer tests leave 406 Hong Kong patients with nervy wait

Hong Kong public hospitals are reviewing blood test results of more than 400 patients after batches of a reagent were found to have quality issues that could produce false positives for prostate cance...

3 days ago - South China Morning Post

Best Dividend Aristocrats For June 2025

Dividend Aristocrats have slightly outperformed the S&P 500 year-to-date, despite underperforming in April and May. Dividend growth remains robust, with 41 of 69 Aristocrats announcing increases in 20...

9 days ago - Seeking Alpha

Abbott Receives FDA Approval for Tendyne™, First-of-Its-Kind Device to Replace the Mitral Valve Without Open-Heart Surgery

The Tendyne system replaces mitral valves that are not functioning properly due to a buildup of calcium in the base of the valves, known as severe mitral annular calcification (MAC) Tendyne offers a n...

10 days ago - PRNewsWire

Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters' Option to Purchase Additional Shares, and Closing of Private Placement

Public offering results in gross proceeds of $57.5 million Private placement results in gross proceeds of approximately $20.3 million GERMANTOWN, Md., May 21, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdi...

16 days ago - Benzinga

Abbott India's quarterly profit climbs 28% on strong demand

Drugmaker Abbott India reported a 28% rise in fourth-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications.

22 days ago - Reuters

Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes

New data reveal a 78% reduction in cardiovascular disease-related hospitalizations for people living with Type 1 diabetes with prior severe low blood sugar episodes.1 This significant decrease is link...

22 days ago - PRNewsWire

Recent Filing Shows That Rep. Bruce Westerman Sold Over $137K Worth of Apple Stock

An official report on May 12, 2025 reveals Representative Bruce Westerman's recent sale of Apple (NASDAQ: AAPL) stock, valued between $137,095 and $1,530,000. The transaction took place on May 12, 20...

24 days ago - Benzinga

Abbott Labs CEO on federal health care spending, investing in healthy people and weight loss drugs

Robert Ford, Abbott Labs CEO, joins 'Power Lunch' to discuss government spending on health care and technological investments.

4 weeks ago - CNBC Television

Abbott Labs CEO on federal health care spending, investing in healthy people and weight loss drugs

Robert Ford, Abbott Labs CEO, joins 'Power Lunch' to discuss government spending on health care and technological investments.

4 weeks ago - CNBC

Jensen Huang, Magic Johnson, Patrick Dempsey, Linda Yaccarino And More Bigwigs Headline Milken Global Conference 2025: What You Need To Know

The Milken Institute's 28th annual Global Conference began on Sunday and will run through May 7 at the Beverly Hilton in Los Angeles. What Happened: Held under the theme “Toward a Flourishing Future,”...

4 weeks ago - Benzinga

US judge allows testimony that Abbott and Mead Johnson preterm baby formula caused deadly disease

A federal judge on Friday said she will allow expert testimony that formula made by Abbott Laboratories and Reckitt Benckiser subsidiary Mead Johnson for premature babies can cause a fatal intestinal ...

5 weeks ago - Reuters

MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races

The test, run on Abbott's portable i-STAT ® Alinity® hand-held instrument, uses whole blood to help evaluate patients 18 years of age and older with a suspected mild traumatic brain injury, or concuss...

5 weeks ago - PRNewsWire

Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom

Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.

5 weeks ago - CNBC

Best Dividend Aristocrats For May 2025

Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Ed...

5 weeks ago - Seeking Alpha

Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information

Collaboration brings together FreeStyle Libre® Systems, the world's leading continuous glucose monitoring technology (CGM)1 with Epic, a healthcare software company, to streamline access to CGM data f...

5 weeks ago - PRNewsWire

A Look Into Abbott Laboratories Inc's Price Over Earnings

In the current market session, Abbott Laboratories Inc. (NYSE: ABT) share price is at $129.36, after a 0.40% spike. Moreover, over the past month, the stock fell by 1.77% , but in the past year, incr...

5 weeks ago - Benzinga

Abbott Laboratories Unveils Promising Data on AVEIR Leadless Pacemaker | ABT stock news

Abbott Laboratories Unveils Promising Data on AVEIR Leadless Pacemaker | ABT stock news

5 weeks ago - GuruFocus

Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology

Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker Enrollment has also b...

5 weeks ago - PRNewsWire

New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib

Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System The 12-month results of the Volt CE ...

5 weeks ago - PRNewsWire

2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market

The Dividend Kings are outperforming the S&P 500 in 2025 by 8.94%. Top performers include National Fuel & Gas (+28.88%), Consolidated Edison (+28.10%), and Middlesex Water Company (+21.00%). Promising...

6 weeks ago - Seeking Alpha

Abbott Labs' Rally Is Well Deserved - Fade The Rally For Now

Abbott's growth potential with GLP-1 tailwinds, robust FCF, and dividend growth. Read more on how ABT navigates tariffs while staying poised to outperform.

6 weeks ago - Seeking Alpha

Abbott Labs is a textbook recession play, says Jim Cramer

'Mad Money' host Jim Cramer checks in on Abbott Labs.

7 weeks ago - CNBC

These Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected Earnings

Abbott Laboratories (NYSE: ABT) reported better-than-expected first-quarter adjusted EPS results on Wednesday. Abbott Laboratories reported first-quarter sales of $10.36 billion, up 7.2% year over ye...

7 weeks ago - Benzinga

These Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected Earnings

Abbott Laboratories ABT reported better-than-expected first-quarter adjusted EPS results on Wednesday.

7 weeks ago - Benzinga